Kubo O, Tajika Y, Toyama T, Tajika T, Sakairi M, Katahira M, Kitamura K
Department of Neurosurgery, Tokyo Women's Medical College, Japan.
No Shinkei Geka. 1988 Aug;16(9):1029-35.
The present study was undertaken to evaluate the utility of pathologic features and specific immunohistochemical studies in estimating the prognosis of oligodendroglioma. The pathological diagnosis of an oligodendroglioma was made on HE stained-sections according to WHO classification. Sixteen oligodendrogliomas, twelve mixed oligoastrocytomas and ten anaplastic oligodendrogliomas were immunotested by the peroxidase-antiperoxidase (PAP) method with anti-GFAP serum, anti-S-100 serum and anti-MBP (Myelin basic protein) serum and by the avidin biotin peroxidase-complex (ABC) method with anti-vimentin serum and ant-Leu 7 monoclonal antibody. GFAP positive cells were interpreted as reactive astrocytes, neoplastic astrocytes and neoplastic oligodendrocytes, S-100 positive cells were interpreted as reactive astrocytes and neoplastic astrocytes. Leu 7 positive cells were found in only one case of anaplastic oligodendroglioma. Anti-Leu 7 could not be considered as a specific marker for oligodendroglioma. Of the anaplastic oligodendroglioma 60% displayed MBP positively and 70% displayed vimentin positively. NSE positive cells were found in a few anaplastic oligodendrogliomas. The present study has not so far uncovered any marker that is restricted to oligodendrogliomas. However GFAP may be useful to assess the extent of reactive astrocytes and neoplastic astrocytes in the oligodendroglioma or mixed oligoastrocytoma. MBP and vimentin will help to determine the malignancy of oligodendroglioma.
本研究旨在评估病理特征和特定免疫组织化学研究在评估少突胶质细胞瘤预后方面的效用。根据世界卫生组织分类,在苏木精-伊红染色切片上做出少突胶质细胞瘤的病理诊断。采用过氧化物酶-抗过氧化物酶(PAP)法,用抗GFAP血清、抗S-100血清和抗MBP(髓鞘碱性蛋白)血清,以及采用抗生物素蛋白-生物素过氧化物酶复合物(ABC)法,用抗波形蛋白血清和抗Leu 7单克隆抗体,对16例少突胶质细胞瘤、12例混合性少突星形细胞瘤和10例间变性少突胶质细胞瘤进行免疫检测。GFAP阳性细胞被解释为反应性星形胶质细胞、肿瘤性星形胶质细胞和肿瘤性少突胶质细胞,S-100阳性细胞被解释为反应性星形胶质细胞和肿瘤性星形胶质细胞。仅在1例间变性少突胶质细胞瘤中发现Leu 7阳性细胞。抗Leu 7不能被视为少突胶质细胞瘤的特异性标志物。间变性少突胶质细胞瘤中,60%显示MBP阳性,70%显示波形蛋白阳性。在少数间变性少突胶质细胞瘤中发现NSE阳性细胞。本研究目前尚未发现任何仅限于少突胶质细胞瘤的标志物。然而,GFAP可能有助于评估少突胶质细胞瘤或混合性少突星形细胞瘤中反应性星形胶质细胞和肿瘤性星形胶质细胞的范围。MBP和波形蛋白将有助于确定少突胶质细胞瘤的恶性程度。